Publications by authors named "Rosa Durandez Lazaro"
Gastroenterol Hepatol
November 2017
Article Synopsis
- The study examined the sustained virological response (SVR) rates in patients who discontinued triple therapy with telaprevir (TLV) or boceprevir (BOV) for non-stopping rule reasons.
- In total, 121 out of 467 treatments were discontinued early, with a notable difference in SVR rates between TLV and BOV, particularly favoring TLV for patients who stopped for reasons unrelated to stopping rules.
- Key predictors for achieving SVR included having undetectable HCV-RNA by week 4 of treatment and a treatment duration of over 11 weeks.
